Please login to the form below

Not currently logged in
Email:
Password:

South Africa to develop HIV, TB and malaria vaccines

South Africa's President, Thabo Mbeki, opens the third branch of the International Centre for Genetic Engineering and Biotechnology in Cape Town

South Africa's President, Thabo Mbeki, has opened the third branch of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Cape Town, according to local media reports.

The centre will conduct vaccine R&D for HIV, malaria, tuberculosis and other infectious diseases affecting the country.

South Africa has spent ZAR 40m (USD 5.6m) on the ICGEB lab, which is located at the University of Cape Town's Institute of Infectious Diseases and Molecular Medicine.

As South Africa's funds were only sufficient to establish three research groups, President Mbeki challenged the international community to donate up to ZAR 120m (USD 17m), which would help to fund seven research programmes slated for a 2010 launch.

Mbeki also invited potential partners to assist and work with the ICGEB to ensure that it realised its objectives.

Nigeria and Tanzania lost out in competitive bids to host the African branch of ICGEB. The other ICGEB sites are located in Trieste, Italy, and New Delhi, India.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics